Acelyrin, a late-stage clinical biopharma company focused on the development and delivery of transformative medicines in immunology, hit the ground running in its first day of trading on Friday, posting roughly a 30 percent gain over its IPO price. The stock then tacked on another 2 percent increase in Monday trading.
